Literature DB >> 12501251

Astroglial c-Myc overexpression predisposes mice to primary malignant gliomas.

Niels A Jensen1, Karen M Pedersen, Frederikke Lihme, Lene Rask, Jakob V Nielsen, Thomas E Rasmussen, Cathy Mitchelmore.   

Abstract

Malignant astrocytomas are common human primary brain tumors that result from neoplastic transformation of astroglia or their progenitors. Here we show that deregulation of the c-Myc pathway in developing astroglia predisposes mice to malignant astrocytomas within 2-3 weeks of age. The genetically engineered murine (GEM) gliomas harbor a molecular signature resembling that of human primary glioblastoma multiforme, including up-regulation of epidermal growth factor receptor and Mdm2. The GEM gliomas seem to originate in an abnormal population of glial fibrillary acidic protein-expressing cells in the ventricular zone and, analogous to human glioblastomas, exhibit molecular and morphological heterogeneity. Levels of connexin 43 in the majority of the tumors are unaltered from normal tissue, indicating that GEM tumors have retained the capacity to establish syncytial networks. In line with this, individual glioma foci are composed of a mixture of actively proliferating cells expressing c-Myc and proliferating cell nuclear antigen and less dividing bystander cells that express glial fibrillary acidic protein and the broad complex tramtrack bric-a-brac/poxvirus and zinc finger domain protein HOF. A subset of the transgenic mice harbored, in addition to brain tumors, vestigial cerebellums in which granule cell migration and radial Bergman glial cell differentiation were disturbed. These observations argue for a window of vulnerability during astrocyte development where c-Myc overexpression is sufficient to trigger the neoplastic process, presumably by inducing the sustained growth of early astroglial cells. This is in contrast to most other transgenic studies in which c-Myc overexpression requires co-operating transgenes for rapid tumor induction.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12501251     DOI: 10.1074/jbc.M211195200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Potential therapeutic implications of cancer stem cells in glioblastoma.

Authors:  Lin Cheng; Shideng Bao; Jeremy N Rich
Journal:  Biochem Pharmacol       Date:  2010-05-10       Impact factor: 5.858

2.  Access to the nucleus and functional association with c-Myc is required for the full oncogenic potential of ΔEGFR/EGFRvIII.

Authors:  Anupama E Gururaj; Laura Gibson; Sonali Panchabhai; MingHui Bai; Ganiraju Manyam; Yue Lu; Khatri Latha; Marta L Rojas; Yeohyeon Hwang; Shoudan Liang; Oliver Bogler
Journal:  J Biol Chem       Date:  2012-12-17       Impact factor: 5.157

Review 3.  Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting.

Authors:  Zhi Huang; Lin Cheng; Olga A Guryanova; Qiulian Wu; Shideng Bao
Journal:  Protein Cell       Date:  2010-07-29       Impact factor: 14.870

4.  TWIST is expressed in human gliomas and promotes invasion.

Authors:  Maria C Elias; Kathleen R Tozer; John R Silber; Svetlana Mikheeva; Mei Deng; Richard S Morrison; Thomas C Manning; Daniel L Silbergeld; Carlotta A Glackin; Thomas A Reh; Robert C Rostomily
Journal:  Neoplasia       Date:  2005-09       Impact factor: 5.715

Review 5.  Turning cancer stem cells inside out: an exploration of glioma stem cell signaling pathways.

Authors:  Zhizhong Li; Hui Wang; Christine E Eyler; Anita B Hjelmeland; Jeremy N Rich
Journal:  J Biol Chem       Date:  2009-03-13       Impact factor: 5.157

6.  Glioblastoma cell growth is suppressed by disruption of Fibroblast Growth Factor pathway signaling.

Authors:  Watcharin Loilome; Avadhut D Joshi; Colette M J ap Rhys; Sara Piccirillo; Angelo L Vescovi; Vescovi L Angelo; Gary L Gallia; Gregory J Riggins
Journal:  J Neurooncol       Date:  2009-04-02       Impact factor: 4.130

Review 7.  Glial progenitors as targets for transformation in glioma.

Authors:  Shirin Ilkhanizadeh; Jasmine Lau; Miller Huang; Daniel J Foster; Robyn Wong; Aaron Frantz; Susan Wang; William A Weiss; Anders I Persson
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

Review 8.  What underlies the diversity of brain tumors?

Authors:  Fredrik J Swartling; Sanna-Maria Hede; William A Weiss
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

9.  Humanized c-Myc mouse.

Authors:  Frank M Lehmann; Samantha Feicht; Florian Helm; Anna Maurberger; Camilla Ladinig; Ursula Zimber-Strobl; Ralf Kühn; Josef Mautner; Armin Gerbitz; Georg W Bornkamm
Journal:  PLoS One       Date:  2012-07-31       Impact factor: 3.240

10.  A statin-regulated microRNA represses human c-Myc expression and function.

Authors:  Apana A L Takwi; Yan Li; Lindsey E Becker Buscaglia; Jingwen Zhang; Saibyasachi Choudhury; Ae Kyung Park; Mofang Liu; Ken H Young; Woong-Yang Park; Robert C G Martin; Yong Li
Journal:  EMBO Mol Med       Date:  2012-08-07       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.